The Experiment, Phase 1: Deliberate Practice

Keyword(s):  
Phase 1 ◽  
2020 ◽  
pp. bmjstel-2019-000520
Author(s):  
Alan Platt ◽  
Peter McMeekin ◽  
Linda Prescott-Clements

BackgroundThe use of simulation has grown in prominence, but variation in the quality of provision has been reported, leading to calls for further research into the most effective instructional designs. Simulation Using Team Deliberate Practice (Sim-TDP) was developed in response. It combines the principles of simulation with deliberate practice, therefore, providing participants with opportunities to work towards well-defined goals, rehearse skills and reflect on performance whilst receiving expert feedback. This study aimed to compare the effects of Sim-TDP, versus the use of traditional simulation, on the performance of second year adult nursing students.MethodsUsing a longitudinal quasi-experimental design, the effects of the two approaches were compared over a 1-year period. Sixteen groups, each containing an average of six participants, were randomised into an intervention arm (n=8) or comparison arm (n=8). Data collection took place at 3 monthly intervals, at which point the performance and time to complete the scenario objectives/tasks, as a team, were recorded and analysed using a validated performance tool.ResultsThe independent t-tests, comparing the performance of the groups, did not demonstrate any notable differences during the three phases. However, in phase 1, the independent t-tests suggested an improvement in the Sim-TDP participants’ time spent on task (t(14) = 5.12, p<0.001), with a mean difference of 7.22 min. The mixed analysis of covariance inferred that the use of the Sim-TDP led to an improvement, over time, in the participants’ performance (F(1, 5) = 12.91, p=0.016), and thus, an association between Sim-TDP and the enhanced performance of participants.ConclusionThe results suggest that Sim-TDP, potentially, optimised participant performance, while maximising the use of Simulation-based education (SBE) resources, such as simulation facilities and equipment. The model could be of practical benefit to nurse educators wishing to integrate SBE into their programmes.


2001 ◽  
Vol 60 (4) ◽  
pp. 215-230 ◽  
Author(s):  
Jean-Léon Beauvois

After having been told they were free to accept or refuse, pupils aged 6–7 and 10–11 (tested individually) were led to agree to taste a soup that looked disgusting (phase 1: initial counter-motivational obligation). Before tasting the soup, they had to state what they thought about it. A week later, they were asked whether they wanted to try out some new needles that had supposedly been invented to make vaccinations less painful. Agreement or refusal to try was noted, along with the size of the needle chosen in case of agreement (phase 2: act generalization). The main findings included (1) a strong dissonance reduction effect in phase 1, especially for the younger children (rationalization), (2) a generalization effect in phase 2 (foot-in-the-door effect), and (3) a facilitatory effect on generalization of internal causal explanations about the initial agreement. The results are discussed in relation to the distinction between rationalization and internalization.


2004 ◽  
Author(s):  
Carl L. Henderson
Keyword(s):  
Phase 1 ◽  

2012 ◽  
Vol 13 (05) ◽  
Author(s):  
A Schmitz ◽  
A Bareksei ◽  
B Paul ◽  
C Schulz
Keyword(s):  

2011 ◽  
Vol 08 (03) ◽  
pp. 150-156
Author(s):  
A. Szegedi

ZusammenfassungDie Medikamentenentwicklung in der Psychiatrie hat kürzlich eine Paradigmenkrise durchlaufen, deren Ursache an verschiedenen allgemeinen Entwicklungen und spezifischen Faktoren im psychiatrischen Fachgebiet liegt. Unter die allgemeinen Entwicklungen fallen deutlich gestiegene Kosten bei der Medikamentenentwicklung und die zunehmende Komplexität bei der Durchführung klinischer Studien, wohingegen sich die Produktivität der Medikamentenentwicklung insgesamt nicht erhöht hat. Die Anforderungen an neue Medikamente der Zulassungsbehörden wie auch der Kostenträger im Gesundheitswesen haben sich generell erhöht. Diese Faktoren zwingen die pharmazeutische Industrie, ihre Ressourcen auf die erfolgversprechendsten Gebiete zu fokussieren. Die spezifischen Probleme der Psychiatrie beinhalten fehlendes detailliertes Wissen zur Pathophysiologie vieler psychiatrischer Störungen, unzureichende prädiktive Tiermodelle, fehlende valide Biomarker, steigende Placeboresponse sowie die grundlegende Problematik der neurobiologisch heterogenen Diagnosen. Aus diesem Grund haben viele forschende Unternehmen bei der Entwicklung neuer Medikamente für die Psychiatrie ihre Prioritäten überdacht. Im Fokus des Artikels stehen Fragen zu Schwächen und potenziellen Risiken im Rahmen psychiatrischer Phase-1- und -2-Studien. Im Lichte dieser jüngsten Entwicklungen werden die spezifischen Probleme für Patienten und Therapeuten aus langfristiger Perspektive diskutiert.


Sign in / Sign up

Export Citation Format

Share Document